Related Experiment Video
Updated: Dec 25, 2025

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
Published on: February 20, 2019
Cardiotrophin-1 Deficiency Abrogates Atherosclerosis Progression
Kapka Miteva1, Daniela Baptista1, Fabrizio Montecucco2,3
1Division of Cardiology, Foundation for Medical Research, Department of Medicine Specialized Medicine, Faculty of Medicine, University of Geneva, Av. de la Roseraie 64, CH-1211, Geneva 4, Switzerland.
Insights
Cardiotrophin-1 (CT-1) deficiency reduces atherosclerosis in mice by lowering cholesterol and improving plaque stability. This involves promoting anti-inflammatory immune cells and regulating key signaling factors, ultimately halting disease progression.
Area of Science:
- Cardiovascular Science
- Immunology
- Molecular Biology
Background:
- Cardiotrophin-1 (CT-1) is implicated in cardiovascular diseases.
- Atherosclerosis is a chronic inflammatory disease of the arteries.
Purpose of the Study:
- To investigate the role of CT-1 deficiency in atherosclerosis development and progression.
- To analyze the impact of CT-1 deficiency on lipid profiles, plaque characteristics, immune cell responses, and paracrine factors in a mouse model.
Main Methods:
- Utilized double knockout Apoe-/-ct-1-/- mice and control Apoe-/- mice fed normal or high-cholesterol diets.
- Quantified serum lipids, intraplaque content, and immune cell populations via flow cytometry.
- Analyzed systemic paracrine factors and aortic sections for atherosclerotic burden.
Main Results:
- Apoe-/-ct-1-/- mice showed reduced total cholesterol, LDL-C, and atherosclerotic plaque size.
- CT-1 deficiency improved plaque stability and promoted atheroprotective immune responses, including increased regulatory T cells, regulatory B cells, and B1a cells.
- CT-1 deficiency modulated specific paracrine factors (IL-3, IL-6, IL-9, IL-15, IL-27, CXCL5, MCP-3, MIP-1α, MIP-1β) associated with anti-inflammatory effects.
Conclusions:
- CT-1 deficiency confers significant anti-atherosclerotic effects in a mouse model.
- Targeting CT-1 may represent a novel therapeutic strategy for managing atherosclerosis and cardiovascular diseases.
Abstract:
Cardiotrophin-1 (CT-1) is associated with cardiovascular (CV) diseases. We investigated the effect of CT-1 deficiency in the development and progression of atherosclerosis in double knockout Apoe-/-ct-1-/- mice. Apoe-/- C57Bl/6 or Apoe-/-ct-1-/- C57Bl/6 mice were fed a normal chow diet (NCD) or a high-cholesterol diet (HCD). After sacrifice, serum triglycerides, total cholesterol, low-density lipoprotein cholesterol (LDL-C), free fatty acids and systemic paracrine factors were measured. Intraplaque lipid and collagen content were quantified in the aortic sections. Immune cell populations in spleen, lymph nodes and aorta were analysis by flow cytometry. Apoe-/-ct-1-/- mice in accelerated atherosclerosis exhibited a reduction of total cholesterol, LDL-C, atherosclerotic plaques size in the aortic root and in the abdominal aorta and improved plaque stability in comparison to Apoe-/- mice. CT-1 deficiency in Apoe-/- mice on (HCD) promoted atheroprotective immune cell responses, as demonstrated by a rise in plasma anti-inflammatory immune cell populations (regulatory T cells, Tregs; regulatory B cells, Bregs and B1a cells) and atheroprotective IgM antibodies. CT-1 deficiency in advanced atherosclerosis mediated regulation of paracrine factors, such as interleukin (IL)-3, IL-6, IL-9, IL-15, IL-27, CXCL5, MCP-3, MIP-1α and MIP-1β. In a model of advanced atherosclerosis, CT-1 deficiency induced anti-inflammatory and atheroprotective effects which resulted in abrogation of atheroprogression.
Related Concept Videos
Atherosclerosis III: Management
Atherosclerosis I: Introduction
Coronary Artery Disease II: Pathophysiology
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Coronary Artery Disease I: Introduction
Cardiomyopathy IV: Restrictive Cardiomyopathy

